Onconase Mediated NFKβ Down-Regulation in Malignant Pleural Mesothelioma

[1]  M. Krzakowski,et al.  Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Atadja,et al.  A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Suneet Shukla,et al.  Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2 , 2009, Drug Metabolism and Disposition.

[4]  S. Bates,et al.  The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. , 2009, Oncology reports.

[5]  C. Porta,et al.  Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma , 2008, Biologics : targets & therapy.

[6]  W. Ardelt,et al.  The cytotoxic ribonuclease onconase targets RNA interference (siRNA) , 2008, Cell cycle.

[7]  J. Testa,et al.  Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis , 2008, Current treatment options in oncology.

[8]  Lidong Zhang,et al.  Bcl‐xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts , 2008, International journal of cancer.

[9]  H. Pass,et al.  Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. , 2008, Future oncology.

[10]  Jue Chen,et al.  Structure, Function, and Evolution of Bacterial ATP-Binding Cassette Systems , 2008, Microbiology and Molecular Biology Reviews.

[11]  Intaek Lee.  Ranpirnase (Onconase®), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy , 2008 .

[12]  H. Pass,et al.  Current concepts in malignant pleural mesothelioma , 2008, Expert review of anticancer therapy.

[13]  S. Bates,et al.  Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. , 2007, Cancer research.

[14]  G. Hillerdal,et al.  Eighth International Mesothelioma Interest Group , 2007, Oncogene.

[15]  E. F. Walton,et al.  Plant Methods Protocol: a Highly Sensitive Rt-pcr Method for Detection and Quantification of Micrornas , 2022 .

[16]  W. Ardelt,et al.  Onconase, an anti-tumor ribonuclease suppresses intracellular oxidative stress. , 2007, International journal of oncology.

[17]  U. Sunar,et al.  The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. , 2007, In vivo.

[18]  W. Ardelt,et al.  Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes. , 2007, Journal of molecular biology.

[19]  T. Efferth,et al.  Chemotherapy-induced resistance by ATP-binding cassette transporter genes. , 2007, Biochimica et biophysica acta.

[20]  R. Bueno,et al.  Inhibitor of apoptosis proteins are regulated by tumour necrosis factor‐α in malignant pleural mesothelioma , 2007, The Journal of pathology.

[21]  Lidong Zhang,et al.  Bcl2/bcl-xl inhibitor engenders apoptosis and increases chemo-sensitivity in mesothelioma , 2007, Cancer biology & therapy.

[22]  T. Gilmore.  Introduction to NF-κB: players, pathways, perspectives , 2006, Oncogene.

[23]  H. Pass,et al.  TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis , 2006, Proceedings of the National Academy of Sciences.

[24]  N. Pavlakis,et al.  Ranpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma , 2006, Expert opinion on biological therapy.

[25]  K. Livak,et al.  Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.

[26]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[27]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[28]  Z. Darżynkiewicz,et al.  Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB. , 2004, International journal of oncology.

[29]  Yoshikazu Nakamura,et al.  Altered expression profiles of microRNAs during TPA-induced differentiation of HL-60 cells. , 2004, Biochemical and biophysical research communications.

[30]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[31]  Terry Gaasterland,et al.  Prediction and identification of Arabidopsis thaliana microRNAs and their mRNA targets , 2004, Genome Biology.

[32]  A. M. George,et al.  The ABC transporter structure and mechanism: perspectives on recent research , 2004, Cellular and Molecular Life Sciences CMLS.

[33]  Sorin Draghici,et al.  Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma , 2004, Clinical Cancer Research.

[34]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[35]  M. Peter,et al.  The TNF Receptor 1 A Split Personality Complex , 2003, Cell.

[36]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[37]  V. Ambros,et al.  MicroRNAs and Other Tiny Endogenous RNAs in C. elegans , 2003, Current Biology.

[38]  T. Tuschl,et al.  New microRNAs from mouse and human. , 2003, RNA.

[39]  W. Ardelt,et al.  Cytotoxic Ribonucleases and RNA Interference (RNAi) , 2003, Cell cycle.

[40]  W. Ardelt,et al.  Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase). , 2002, International journal of oncology.

[41]  R. Sirdeshmukh,et al.  Entry into Cells and Selective Degradation of tRNAs by a Cytotoxic Member of the RNase A Family* , 2002, The Journal of Biological Chemistry.

[42]  V. Rusch,et al.  Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  Y. Soini,et al.  The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  D. Newton,et al.  Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. , 2000, Cancer research.

[45]  T. Gilmore,et al.  The Rel/NF-κB signal transduction pathway: introduction , 1999, Oncogene.

[46]  Y. Soini,et al.  Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  R. Robledo,et al.  Cellular and molecular mechanisms of asbestos‐induced fibrosis , 1999, Journal of cellular physiology.

[48]  W. Ardelt,et al.  Potentiation of tumor necrosis factor induced apoptosis by onconase. , 1998, International journal of oncology.

[49]  J Deisenhofer,et al.  Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. , 1996, Journal of molecular biology.

[50]  D. Newton,et al.  Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. , 1996, Journal of the National Cancer Institute.

[51]  W. J. Matthews,et al.  Characteristics of nine newly derived mesothelioma cell lines. , 1995, The Annals of thoracic surgery.

[52]  S. Rybak,et al.  A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. , 1993, The Journal of biological chemistry.

[53]  Z. Darżynkiewicz,et al.  Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. , 1992, British Journal of Cancer.

[54]  R. Raines,et al.  Ribonucleases as novel chemotherapeutics : the ranpirnase example. , 2008, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[55]  Intaek Lee.  Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. , 2008, Expert Opinion on Biological Therapy.

[56]  A. Gewirtz,et al.  Possible mechanisms of improved radiation response by cytotoxic RNase, Onconase, on A549 human lung cancer xenografts of nude mice. , 2007, Advances in experimental medicine and biology.

[57]  T. Gilmore,et al.  Introduction to NF-kappaB: players, pathways, perspectives. , 2006, Oncogene.

[58]  Ronald T. Raines,et al.  Ribonuclease inhibitor: structure and function. , 2005, Progress in nucleic acid research and molecular biology.

[59]  T. Gilmore,et al.  The Rel/NF-κB/IκB Signal Transduction Pathway and Cancer , 2004 .

[60]  T. Gilmore,et al.  The Re1/NF-kappa B/I kappa B signal transduction pathway and cancer. , 2003, Cancer treatment and research.

[61]  T. Gilmore.  The Rel/NF-kappaB signal transduction pathway: introduction. , 1999, Oncogene.